Skip to main content

Neurocrine Biosciences Inc's Form 4 filing

Voyager Therapeutics, Inc.VYGR · filed Feb 24, 2023

Accession no.
0000899243-23-006093
Filed
Feb 24, 2023
Trade date
Feb 23, 2023
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 1 non-derivative transaction. Open-market purchases total $39.0M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Neurocrine Biosciences IncCIK 000091447510% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 23, 2023Common StockPPurchaseAcquired+4,395,588$8.88F1+$39,032,821.448,575,316Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The purchase price was determined in accordance with that certain Stock Purchase Agreement dated January 8, 2023, between the reporting person and the issuer.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)